U.S. Markets close in 2 hrs 30 mins

Oncorus, Inc. (ONCR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.3238+0.0036 (+1.12%)
As of 01:01PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.3202
Bid0.3206 x 1300
Ask0.3261 x 1000
Day's Range0.3203 - 0.3613
52 Week Range0.2300 - 1.9800
Avg. Volume343,773
Market Cap8.41M
Beta (5Y Monthly)2.90
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • American City Business Journals

    Cancer biotech cuts staff by one-fifth

    Boston biotech Oncorus Inc. is losing one-fifth of its employees as it pauses work on all but one drug. Oncorus (Nasdaq: ONCR) announced the cuts on Wednesday, saying it will lay off 20% of its staff. ONCR-021 is still preclinical, but Oncorus believes it could have applications in non-small cell lung cancer, hepatocellular carcinoma, clear cell renal cell carcinoma and melanoma.

  • Benzinga

    Oncorus Pulls Plug On Phase 1 Candidate, Lays Off 20% Of Its Workforce

    Oncorus Inc (NASDAQ: ONCR) is reprioritizing its pipeline and is discontinuing the Phase 1 trial of ONCR-177 to focus resources on ONCR-021. In addition, the company is discontinuing the development of ONCR-177, reducing its workforce and burn rate, and reiterating guidance for its cash runway into early 2024. Oncorus will present the results of the Phase 1 study of ONCR-177 in patients with advanced disease in conjunction with a scientific congress in 2023. Related: Chardan Sees Over 200% Upsid

  • Zacks

    Oncorus, Inc. (ONCR) Moves to Buy: Rationale Behind the Upgrade

    Oncorus, Inc. (ONCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).